Clinical Trials Logo

Clinical Trial Summary

A Prospective Randomized Open-Label Blinded Endpoint (PROBE) Pilot Trial of restarting antiplatelet therapy at 1 week versus 3 weeks after traumatic intracranial hemorrhage with a primary composite endpoint of major bleeding and vascular occlusive events.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05000060
Study type Interventional
Source University of Texas at Austin
Contact Truman J Milling, MD
Phone 15124969742
Email tjmilling@yahoo.com
Status Not yet recruiting
Phase Phase 3
Start date October 1, 2022
Completion date October 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT05609734 - No Cases of Delayed Intracranial Hemorrhage (d-ICH) Among Patients With Mild Traumatic Brain Injury (mTBI) on Oral Anticoagulation Therapy
Completed NCT05609721 - Mild Traumatic Brain Injury and the Risk for Traumatic Intracranial Hemorrhage
Enrolling by invitation NCT06433622 - Platelet Transfusion and Repeat TEG-PM in Patients With Severe TBI on Antiplatelet Therapy (Repeat TEG-PM)
Completed NCT02728908 - Detecting Traumatic Intracranial Hemorrhage With Microwave Technology N/A